Company Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.
The company was founded in 2012 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Mar 12, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Angelos M. Stergiou M.D., ScD h.c. |
Contact Details
Address: Times Square Tower New York, New York United States | |
| Website | https://www.sellaslifesciences.com |
Stock Details
| Ticker Symbol | SLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001390478 |
| CUSIP Number | 81642T209 |
| ISIN Number | US81642T2096 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer & Director |
| John Thomas Burns CPA | Senior Vice President & Chief Financial Officer |
| Andrew Elnatan | Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development |
| Stacy E. Yeung | Vice President, Associate General Counsel & Head of Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 04, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |